A multiple reader scoring system for Nasal Potential Difference parameters

Journal of Cystic Fibrosis

Volumn 16, Issue 5, 2017, Pages 573-578

  Solomon, George M ^a   Liu, Bo ^a   Sermet Gaudelus, Isabelle ^b,c   Fajac, Isabelle ^c,d   Wilschanski, Michael ^e   Vermeulen, Francois ^f   Rowe, Steven M ^a  

^a University of Alabama at Birmingham   (United States)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Service de Physiologie et Explorations Fonctionnelles ^*  (France)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

CFTR; Clinical trial outcomes; Nasal Potential Difference

Indexed keywords

AMILORIDE; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ISOPRENALINE; SODIUM;

ALGORITHM; ARTICLE; CHLORIDE TRANSPORT; FIBROSIS; INTERRATER RELIABILITY; POTENTIAL DIFFERENCE; QUALITATIVE ANALYSIS; SCORING SYSTEM; SODIUM TRANSPORT; CYSTIC FIBROSIS; HUMAN; MEMBRANE POTENTIAL; METABOLISM; METHODOLOGY; NOSE MUCOSA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; REPRODUCIBILITY; STANDARD; STANDARDS;

ALGORITHMS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MEMBRANE POTENTIALS; MONITORING, PHYSIOLOGIC; NASAL MUCOSA; OUTCOME ASSESSMENT (HEALTH CARE); REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 85018344290     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2017.04.011     Document Type: Article

References (28)

1. Knowles, M.R., Carson, J.L., Collier, A.M., Gatzy, J.T., Boucher, R.C., Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 124:4 (1981), 484–490.
2. Knowles, M.R., Buntin, W.H., Bromberg, P.A., Gatzy, J.T., Boucher, R.C., Measurements of transepithelial electric potential differences in the trachea and bronchi of human subjects in vivo. Am Rev Respir Dis 126:1 (1982), 108–112.
3. Knowles, M.R., Stutts, M.J., Yankaskas, J.R., Gatzy, J.T., Boucher, R.C. Jr., Abnormal respiratory epithelial ion transport in cystic fibrosis. Clin Chest Med 7:2 (1986), 285–297.
4. Standaert, T.A., Boitano, L., Emerson, J., Milgram, L.J., Konstan, M.W., Hunter, J., et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 37:5 (2004), 385–392.
5. Schuler, D., Sermet-Gaudelus, I., Wilschanski, M., Ballmann, M., Dechaux, M., Edelman, A., et al. Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 3:Suppl. 2 (2004), 151–155.
6. + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 78:5 (1986), 1245–1252.
7. Gowen, C.W., Lawson, E.E., Gingras-Leatherman, J., Gatzy, J.T., Boucher, R.C., Knowles, M.R., Increased nasal potential difference and amiloride sensitivity in neonates with cystic fibrosis. J Pediatr 108:4 (1986), 517–521.
8. Knowles, M.R., Stutts, M.J., Spock, A., Fischer, N., Gatzy, J.T., Boucher, R.C., Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 221:4615 (1983), 1067–1070.
9. Knowles, M.R., Clarke, L.L., Boucher, R.C., Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 325:8 (1991), 533–538.
10. Accurso, F.J., Rowe, S.M., Clancy, J.P., Boyle, M.P., Dunitz, J.M., Durie, P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363:21 (2010), 1991–2003.
11. Clancy, J.P., Rowe, S.M., Accurso, F.J., Aitken, M.L., Amin, R.S., Ashlock, M.A., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67:1 (2012), 12–18.
12. Clancy, J.P., Rowe, S.M., Bebok, Z., Aitken, M.L., Gibson, R., Zeitlin, P., et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 37:1 (2007), 57–66.
13. Wilschanski, M., Miller, L.L., Shoseyov, D., Blau, H., Rivlin, J., Aviram, M., et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38:1 (2011), 59–69.
14. Boucher, R.C., Knowles, M.R., Johnson, L.G., Olsen, J.C., Pickles, R., Wilson, J.M., et al. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. Hum Gene Ther 5:5 (1994), 615–639.
15. Knowles, M.R., Hohneker, K.W., Zhou, Z., Olsen, J.C., Noah, T.L., Hu, P.C., et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 333:13 (1995), 823–831.
16. Noone, P.G., Hohneker, K.W., Zhou, Z., Johnson, L.G., Foy, C., Gipson, C., et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 1:1 (2000), 105–114.
17. Alton, E.W., Boyd, A.C., Porteous, D.J., Davies, G., Davies, J.C., Griesenbach, U., et al. A phase I/IIa safety and efficacy study of nebulized liposome-mediated gene therapy for cystic fibrosis supports a multidose trial. Am J Respir Crit Care Med 192:11 (2015), 1389–1392.
18. Alton, E.W., Armstrong, D.K., Ashby, D., Bayfield, K.J., Bilton, D., Bloomfield, E.V., et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3:9 (2015), 684–691.
19. Knowles, M.R., Church, N.L., Waltner, W.E., Yankaskas, J.R., Gilligan, P., King, M., et al. Aerosolized amiloride as treatment of cystic fibrosis lung disease: a pilot study. Adv Exp Med Biol 290 (1991), 119–128 [discussion 29-32].
20. Knowles, M.R., Church, N.L., Waltner, W.E., Yankaskas, J.R., Gilligan, P., King, M., et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 322:17 (1990), 1189–1194.
21. Hofmann, T., Stutts, M.J., Ziersch, A., Ruckes, C., Weber, W.M., Knowles, M.R., et al. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am J Respir Crit Care Med 157:6 Pt 1 (1998), 1844–1849.
22. Rowe, S.M., Reeves, G., Hathorne, H., Solomon, G.M., Abbi, S., Renard, D., et al. Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis. Chest 144:1 (2013), 200–207.
23. Rowe, S.M., Liu, B., Hill, A., Hathorne, H., Cohen, M., Beamer, J.R., et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One, 8(7), 2013, e66955.
24. Solomon, G.M., Konstan, M.W., Wilschanski, M., Billings, J., Sermet-Gaudelus, I., Accurso, F., et al. An international randomized multicenter comparison of nasal potential difference techniques. Chest 138:4 (2010), 919–928.
25. Rowe, S.M., Clancy, J.P., Wilschanski, M., Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol 741 (2011), 69–86.
26. Farrell, P.M., Rosenstein, B.J., White, T.B., Accurso, F.J., Castellani, C., Cutting, G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153:2 (2008), S4–S14.
27. Landis, J.R., Koch, G.G., The measurement of observer agreement for categorical data. Biometrics 33:1 (1977), 159–174.
28. Naehrlich, L., Ballmann, M., Davies, J., Derichs, N., Gonska, T., Hjelte, L., et al. Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. J Cyst Fibros 13:1 (2014), 24–28.